Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

NCT03451331 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Urothelial Cancer

Interventions

DRUG: Nivolumab
DRUG: Gemcitabine
DRUG: Carboplatin
DRUG: Oxaliplatin

Sponsor

Matthew Galsky

Collaborators

[object Object]
[object Object]